Skip to main content
S&P 5007,805.45-0.02%DOW51,670.10-0.35%NASDAQ27,204.38-0.15%BTC$83,175.00+0.22%ETH$2,506.63-0.64%GOLD$4,186.10-0.11%OIL$94.78+1.11%
Smart Investors Daily
SID Premium
CC

NASDAQ · CCCC

C4 Therapeutics, Inc.

Healthcare · Biotechnology

$3.06

Down-$0.25 (-8.03%)

Updated Oct 13, 2026, 7:36 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
180.43M
P/E ratio
-1.54
Dividend yield
0.00%
52-week range
$2.30 – $5.17
Volume
1.5M
Avg. volume
2.1M

Price performance · CCCC

CCCC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 12, 2026

CCCC closed at $3.06 after 21 trading sessions, down 10.79% for the selected period.

Last close
$3.06
Period change
-10.79%
Period low
$2.82
Period high
$3.45
Daily close
View OHLC price history
CCCC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 12, 2026$3.16$3.30$3.05$3.061.5M
Oct 9, 2026$3.00$3.1899$2.95$3.162.51M
Oct 8, 2026$2.80$2.88$2.7211$2.852.83M
Oct 7, 2026$2.85$2.95$2.82$2.822.27M
Oct 6, 2026$3.02$3.03$2.79$2.882.11M
Oct 5, 2026$3.01$3.10$2.95$2.991.46M
Oct 2, 2026$3.19$3.33$2.93$2.953.38M
Oct 1, 2026$3.31$3.37$3.135$3.141.89M
Sep 30, 2026$3.16$3.37$3.13$3.332.61M
Sep 29, 2026$3.09$3.215$3.00$3.131.55M
Sep 28, 2026$3.015$3.16$2.98$3.1152.78M
Sep 25, 2026$3.03$3.115$2.925$2.982.12M
Sep 24, 2026$3.03$3.06$2.88$3.032.81M
Sep 23, 2026$3.32$3.34$2.925$3.084.59M
Sep 22, 2026$3.33$3.42$3.285$3.311.36M
Sep 21, 2026$3.44$3.45$3.245$3.302.05M
Sep 18, 2026$3.43$3.475$3.38$3.391.63M
Sep 17, 2026$3.51$3.59$3.40$3.4151.76M
Sep 16, 2026$3.44$3.53$3.425$3.452.32M
Sep 15, 2026$3.40$3.455$3.32$3.431.34M
Sep 14, 2026$3.46$3.54$3.41$3.431.49M

Latest CCCC news

The latest Smart Investors Daily articles mentioning CCCC.

Stock researchCompany · Overview

CCCC research

Overview

Company profile and research snapshot.

Company profile

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.67
Implied upside
—
Analysts
—
CCCC recent ratings
DateFirmRatingTarget
Oct 9, 2026JP MorganOverweight—
Jun 1, 2026Evercore ISI GroupOutperform—
Feb 27, 2026BarclaysOverweight—
Feb 23, 2026Brookline CapitalBuy—
Dec 17, 2025BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to Drive T-cell Expansion and Activation, and Prevent T-cell Exhaustion When Combined with Immune-based Therapies First Cemsidomide Dose Level (75 µg) in Phase 1b Trial with Elranatamab Declared Safe by S

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By